TAKE Solutions Limited (TAKE.NS)
INR 8.0
(-0.37%)
INR 8.0
(-0.37%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.19 Billion INR | -19.3% |
| 2022 | -1 Billion INR | 87.18% |
| 2021 | -7.82 Billion INR | -73.06% |
| 2020 | -4.52 Billion INR | -3557.15% |
| 2019 | -123.6 Million INR | -106.97% |
| 2018 | 1.77 Billion INR | 10.5% |
| 2017 | 1.6 Billion INR | 22.75% |
| 2016 | 1.3 Billion INR | 9.25% |
| 2015 | 1.19 Billion INR | 71.22% |
| 2014 | 698.83 Million INR | 20.49% |
| 2013 | 580 Million INR | -27.02% |
| 2012 | 794.7 Million INR | -15.6% |
| 2011 | 941.59 Million INR | 28.02% |
| 2010 | 735.51 Million INR | 102.7% |
| 2009 | 362.86 Million INR | -32.8% |
| 2008 | 539.98 Million INR | 0.12% |
| 2007 | 539.35 Million INR | 63.24% |
| 2006 | 330.41 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q3 | -21.36 Million INR | -37.9% |
| 2023 Q4 | -1.1 Billion INR | -5078.56% |
| 2023 FY | -1.19 Billion INR | -19.3% |
| 2023 Q1 | -53.21 Million INR | 90.46% |
| 2023 Q2 | -15.49 Million INR | 70.89% |
| 2022 Q4 | -557.83 Million INR | -448.72% |
| 2022 FY | -1 Billion INR | 87.18% |
| 2022 Q2 | -81.89 Million INR | -50.65% |
| 2022 Q3 | -101.66 Million INR | -24.13% |
| 2022 Q1 | -54.36 Million INR | 99.25% |
| 2021 Q3 | -418.44 Million INR | -370.73% |
| 2021 Q4 | -7.28 Billion INR | -1640.65% |
| 2021 FY | -7.82 Billion INR | -73.06% |
| 2021 Q2 | -88.89 Million INR | -178.27% |
| 2021 Q1 | -31.94 Million INR | 95.44% |
| 2020 Q2 | -1.15 Billion INR | 52.26% |
| 2020 Q3 | -254.57 Million INR | 77.97% |
| 2020 Q4 | -700.8 Million INR | -175.29% |
| 2020 FY | -4.52 Billion INR | -3557.15% |
| 2020 Q1 | -2.42 Billion INR | -53.26% |
| 2019 Q4 | -1.57 Billion INR | -413.11% |
| 2019 Q2 | 500.24 Million INR | 10.9% |
| 2019 Q1 | 451.07 Million INR | 61.8% |
| 2019 FY | -123.6 Million INR | -106.97% |
| 2019 Q3 | 504.38 Million INR | 0.83% |
| 2018 Q1 | 534.16 Million INR | 16.49% |
| 2018 Q3 | 357.61 Million INR | -40.63% |
| 2018 Q4 | 278.78 Million INR | -22.04% |
| 2018 FY | 1.77 Billion INR | 10.5% |
| 2018 Q2 | 602.38 Million INR | 12.77% |
| 2017 Q4 | 458.55 Million INR | 9.28% |
| 2017 FY | 1.6 Billion INR | 22.75% |
| 2017 Q3 | 419.59 Million INR | 12.24% |
| 2017 Q2 | 373.83 Million INR | 3.54% |
| 2017 Q1 | 361.05 Million INR | 4.9% |
| 2016 FY | 1.3 Billion INR | 9.25% |
| 2016 Q1 | 314.27 Million INR | 1.0% |
| 2016 Q2 | 326.63 Million INR | 3.93% |
| 2016 Q3 | 322.11 Million INR | -1.39% |
| 2016 Q4 | 344.18 Million INR | 6.85% |
| 2015 Q4 | 311.15 Million INR | 29.72% |
| 2015 FY | 1.19 Billion INR | 71.22% |
| 2015 Q3 | 239.87 Million INR | -4.26% |
| 2015 Q2 | 250.54 Million INR | -36.57% |
| 2015 Q1 | 394.97 Million INR | 45.82% |
| 2014 Q2 | 133.99 Million INR | 3.14% |
| 2014 Q1 | 129.92 Million INR | 0.78% |
| 2014 FY | 698.83 Million INR | 20.49% |
| 2014 Q4 | 270.87 Million INR | 65.13% |
| 2014 Q3 | 164.03 Million INR | 22.42% |
| 2013 Q1 | 132.48 Million INR | -13.88% |
| 2013 Q2 | 151.27 Million INR | 14.18% |
| 2013 Q3 | 167.33 Million INR | 10.62% |
| 2013 FY | 580 Million INR | -27.02% |
| 2013 Q4 | 128.91 Million INR | -22.96% |
| 2012 Q1 | 252.03 Million INR | -19.02% |
| 2012 Q2 | 210.87 Million INR | -16.33% |
| 2012 FY | 794.7 Million INR | -15.6% |
| 2012 Q4 | 153.84 Million INR | -13.54% |
| 2012 Q3 | 177.94 Million INR | -15.62% |
| 2011 Q3 | 213.01 Million INR | 5.61% |
| 2011 FY | 941.59 Million INR | 28.02% |
| 2011 Q2 | 201.7 Million INR | 0.0% |
| 2011 Q4 | 311.22 Million INR | 46.1% |
| 2010 FY | 735.51 Million INR | 102.7% |
| 2009 FY | 362.86 Million INR | -32.8% |
| 2008 FY | 539.98 Million INR | 0.12% |
| 2007 FY | 539.35 Million INR | 63.24% |
| 2006 FY | 330.41 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Biocon Limited | 10.22 Billion INR | 111.699% |
| Blue Jet Healthcare Limited | 1.63 Billion INR | 173.05% |
| Concord Biotech Limited | 3.08 Billion INR | 138.825% |
| Dishman Carbogen Amcis Limited | -1.53 Billion INR | 22.046% |
| Jubilant Ingrevia Limited | 1.82 Billion INR | 165.406% |
| Lyka Labs Limited | -24.89 Million INR | -4705.174% |
| Panacea Biotec Limited | -11.73 Million INR | -10097.783% |
| Piramal Pharma Limited | 178.2 Million INR | 771.268% |
| SMS Lifesciences India Limited | 90.92 Million INR | 1415.546% |
| Supriya Lifescience Limited | 1.19 Billion INR | 200.425% |
| Syngene International Limited | 5.1 Billion INR | 123.455% |
| Zota Health Care Limited | -143.47 Million INR | -733.711% |